Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  INDONESIA STOCK EXCHANGE  >  PT Kalbe Farma Tbk.    KLBF   ID1000125107


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Kalbe Farma Tbk PT : Commemorates World Hepatitis Day

share with twitter share with LinkedIn share with facebook
share via e-mail
09/28/2019 | 09:18am EST

Press Release No. 028/KFCP-DIR/PR/VII/19

Jakarta, July 28, 2019 - PT Kalbe Farma Tbk (Kalbe) today in collaboration with the Indonesian Heart Research Association (PPHI) held a campaign and health education with reference of the World Hepatitis Day with the theme Find the Missing Millions that is launched worldwide. The commemoration of World Hepatitis Day is carried out by distributing educational material about hepatitis to people who are having activities during Car Free Day in front of the Pullman Hotel Jakarta. This campaign activity was attended by Dr. dr. Irsan Hasan, SpPD-KGEH, FINASIM, Chairman of the Indonesian Heart Research Association; Ridwan Ong, Marketing Director of PT Kalbe Farma Tbk; as well as Internists and Gastroentero Hepatology Consultants from all over Indonesia and also people concerned with hepatitis.

'Kalbe is committed in improving health for a better life for the entire community, including efforts to prevent hepatitis,' said Ridwan Ong, Marketing Director of PT Kalbe Farma Tbk. 'Through this activity we want to increase public awareness about hepatitis, so that they can prevent and manage hepatitis symptoms. This is in line with the Hepatitis control program carried out by the Government through efforts to increase advocacy, technical, and general knowledge about hepatitis virus to community members,' Ridwan continued.

'Hepatitis is one of the infectious diseases that should get the attention of all of us, in Indonesia, the type of hepatitis that more often infects our population is Hepatitis B,' said Dr. dr. Irsan Hasan, SpPD-KGEH, FINASIM, Chair of the Indonesian Liver Research Association. The type of virus in each type of hepatitis are different so the treatment is different. Through today's activity we want to build public awareness to check themselves to find out whether they are infected with hepatitis or not. If not, they are expected to get vaccinated for hepatitis. But if they are infected, they can undergo treatment.' added Dr. Irsan.

As we all know that Hepatitis is a public health problem in the world including in Indonesia, which consists of Hepatitis A, B, C, D and E. Hepatitis B is a type of hepatitis virus that is most often found in Indonesia, which is caused by the hepatitis B virus (HBV). In 2015, approximately 257 million people worldwide had chronic hepatitis B (lasting more than 6 months) and caused 887,000 deaths. Transmission of the hepatitis B virus can happen through contact with blood or body fluids with hepatitis B. The symptoms and signs of hepatitis B are not specific and most sufferers do not experience symptoms at the onset of infection.

Symptoms and signs of hepatitis B include mild fever, lethargy, decreased appetite, nausea, vomiting, right abdominal pain, mild enlargement of the liver, may be accompanied by jaundice (yellowing on the skin and eye sclera) and tea-colored dark urine. Chronic hepatitis B can develop into cirrhosis (formation of scar tissue in the liver) and liver cancer.

Hepatitis B immunization is very important to prevent transmission of hepatitis B, one of which is by giving the hepatitis B vaccine 3 times, in months 0, 1st, and 6th. It is recommended that all babies get the hepatitis B vaccine as soon as possible after birth, 2nd, 4th, and 6th month. It is also important to have a healthy lifestyle and avoid direct contact with blood or body fluid of people with hepatitis B; by not exchanging toothbrushes, razors or nail clippers, not using syringes that are likely to be contaminated with the hepatitis B virus, and not having sexual contact with a person with hepatitis B without protection (condom). (source: WHO Hepatitis fact sheets 2019)

Kalbe at a glance
PT Kalbe Farma Tbk ('Kalbe') was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); energy and ready-to-consume drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has approximately 38 subsidiaries and 12 production facilities with international standard, and employs approximately 17,000 employees dispersed across more than 76 branches throughout Indonesia.
From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX: KLBF).



PT Kalbe Farma Tbk published this content on 28 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2019 13:17:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PT KALBE FARMA TBK.
02/05KALBE FARMA TBK PT : Change of Corporate Secretary of PT Kalbe Farma Tbk
2019KALBE FARMA TBK PT : Disclosure of Information - Increased in Issued and Paid in..
2019KALBE FARMA TBK PT : Disclosure of Information - Increased in Issued and Paid in..
2019KALBE FARMA TBK PT : Growth Improvement in Sales and Net Income
2019Indonesia hikes state health insurer's premiums to plug deficit
2019KALBE FARMA TBK PT : Disclosure of Information - Establishment of a Subsidiary, ..
2019KALBE FARMA TBK PT : Will Participate In CPhI In Frankfurt
2019KALBE FARMA TBK PT : Commemorates World Hepatitis Day
2019KALBE FARMA TBK PT : Genexine Biologics Enters Into an Exclusive Licensing of Im..
2019KALBE FARMA TBK PT : Maintain Better Company Performance
More news
Financials (IDR)
Sales 2019 22 827 B
EBIT 2019 3 489 B
Net income 2019 2 646 B
Finance 2019 2 774 B
Yield 2019 2,14%
P/E ratio 2019 21,6x
P/E ratio 2020 20,4x
EV / Sales2019 2 505x
EV / Sales2020 2 341x
Capitalization 57 188 B
Duration : Period :
PT Kalbe Farma Tbk. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 1 682,50  IDR
Last Close Price 1 220,00  IDR
Spread / Highest target 63,9%
Spread / Average Target 37,9%
Spread / Lowest Target -1,64%
EPS Revisions
Vidjongtius President Director
Bernadette Ruth Setiady President Commissioner
Dino Bramanto Head-Corporate Information Technology & System
Santoso Oen Commissioner
Ferdinand Aryanto Commissioner
Sector and Competitors
1st jan.Capitalization (M$)
PT KALBE FARMA TBK.-3.10%3 980
JOHNSON & JOHNSON-4.63%354 317
ROCHE HOLDING AG2.69%271 765
MERCK AND COMPANY-15.82%194 177
NOVARTIS-7.45%190 125
PFIZER, INC.-12.97%185 402